News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
118,550 Results
Type
Article (10094)
Company Profile (22)
Press Release (108433)
Multimedia
Podcasts (28)
Webinars (4)
Section
Business (29757)
Career Advice (612)
Deals (6121)
Drug Delivery (41)
Drug Development (12405)
Employer Resources (71)
FDA (3919)
Job Trends (3757)
News (53746)
Policy (6228)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (705)
Accelerated approval (9)
Adcomms (6)
Allergies (42)
Alliances (9970)
ALS (41)
Alzheimer's disease (332)
Antibody-drug conjugate (ADC) (63)
Approvals (4007)
Artificial intelligence (106)
Autoimmune disease (18)
Automation (11)
Bankruptcy (40)
Best Places to Work (3227)
BIOSECURE Act (5)
Biosimilars (46)
Biotechnology (9)
Bladder cancer (36)
Brain cancer (14)
Breast cancer (158)
Cancer (928)
Cardiovascular disease (133)
Career advice (540)
Career pathing (11)
CAR-T (44)
CDC (16)
Cell therapy (137)
Cervical cancer (8)
Clinical research (10609)
Collaboration (360)
Company closure (1)
Compensation (79)
Complete response letters (18)
COVID-19 (820)
CRISPR (23)
C-suite (144)
Cystic fibrosis (32)
Data (1066)
Decentralized trials (1)
Denatured (7)
Depression (28)
Diabetes (145)
Diagnostics (1388)
Digital health (12)
Diversity (3)
Diversity, equity & inclusion (15)
Drug discovery (39)
Drug pricing (64)
Drug shortages (13)
Duchenne muscular dystrophy (63)
Earnings (9847)
Editorial (32)
Employer branding (7)
Employer resources (63)
Events (15653)
Executive appointments (140)
FDA (4619)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (2)
Frontotemporal dementia (6)
Funding (258)
Gene editing (53)
Generative AI (9)
Gene therapy (157)
GLP-1 (269)
Government (1224)
Grass and pollen (4)
Guidances (107)
Healthcare (3894)
HIV (23)
Huntington's disease (11)
IgA nephropathy (13)
Immunology and inflammation (55)
Immuno-oncology (9)
Indications (25)
Infectious disease (898)
Inflammatory bowel disease (38)
Inflation Reduction Act (5)
Influenza (28)
Intellectual property (57)
Interviews (107)
IPO (2266)
IRA (19)
Job creations (667)
Job search strategy (466)
JPM (27)
Kidney cancer (3)
Labor market (32)
Layoffs (209)
Leadership (13)
Legal (1131)
Liver cancer (17)
Longevity (2)
Lung cancer (139)
Lymphoma (83)
Machine learning (7)
Management (26)
Manufacturing (211)
MASH (27)
Medical device (3118)
Medtech (3128)
Mergers & acquisitions (4097)
Metabolic disorders (389)
Multiple sclerosis (43)
NASH (4)
Neurodegenerative disease (67)
Neuropsychiatric disorders (24)
Neuroscience (610)
Neurotech (1)
NextGen: Class of 2026 (1286)
Non-profit (1556)
Now hiring (23)
Obesity (209)
Opinion (106)
Ovarian cancer (30)
Pain (24)
Pancreatic cancer (33)
Parkinson's disease (60)
Partnered (8)
Patents (95)
Patient recruitment (57)
Peanut (16)
People (8136)
Pharmaceutical (10)
Pharmacy benefit managers (10)
Phase 1 (2488)
Phase 2 (3957)
Phase 3 (4928)
Pipeline (1040)
Policy (98)
Postmarket research (482)
Preclinical (847)
Press Release (11)
Prostate cancer (57)
Psychedelics (24)
Radiopharmaceuticals (45)
Rare diseases (251)
Real estate (1140)
Recruiting (30)
Regulatory (4981)
Reports (18)
Research institute (633)
Resumes & cover letters (76)
Rett syndrome (2)
RNA editing (3)
RSV (29)
Schizophrenia (33)
Series A (40)
Series B (30)
Sickle cell disease (36)
Special edition (8)
Spinal muscular atrophy (52)
Sponsored (11)
Startups (638)
Stomach cancer (6)
Supply chain (38)
Tariffs (26)
The Weekly (21)
Vaccines (346)
Venture capital (32)
Weight loss (151)
Women's health (31)
Worklife (3)
Date
Last 7 days (117)
Last 30 days (383)
Last 365 days (5075)
2026 (504)
2025 (5137)
2024 (6169)
2023 (7064)
2022 (10974)
2021 (10909)
2020 (10810)
2019 (10246)
2018 (7914)
2017 (6289)
2016 (6242)
2015 (6539)
2014 (4709)
2013 (3549)
2012 (3671)
2011 (3624)
2010 (2703)
Location
Africa (268)
Alabama (7)
Alaska (3)
Arizona (31)
Arkansas (1)
Asia (8673)
Australia (1490)
California (1367)
Canada (422)
China (255)
Colorado (50)
Connecticut (39)
Delaware (38)
Europe (20171)
Florida (144)
Georgia (21)
Idaho (5)
Illinois (166)
India (14)
Indiana (225)
Iowa (2)
Japan (144)
Kansas (56)
Kentucky (5)
Louisiana (8)
Maine (31)
Maryland (279)
Massachusetts (1205)
Michigan (56)
Minnesota (69)
Mississippi (1)
Missouri (33)
Montana (1)
Nebraska (7)
Nevada (14)
New Hampshire (14)
New Jersey (766)
New Mexico (1)
New York (460)
North Carolina (214)
North Dakota (4)
Northern California (627)
Ohio (90)
Oklahoma (2)
Oregon (10)
Pennsylvania (285)
Puerto Rico (2)
Rhode Island (9)
South America (313)
South Carolina (5)
Southern California (553)
Tennessee (28)
Texas (139)
United States (5838)
Utah (35)
Virginia (47)
Washington D.C. (17)
Washington State (92)
West Virginia (1)
Wisconsin (24)
118,550 Results for "aro biotherapeutics.rss".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Sensorion Announces its Participation in the Association for Research in Otolaryngology ARO 49th Annual Midwinter Meeting
February 6, 2026
·
3 min read
Press Releases
Aro Biotherapeutics to Present Clinical Update from its Pompe Disease Program at the 22nd Annual WORLDSymposium
January 20, 2026
·
2 min read
Press Releases
Aro Biotherapeutics Reports Preliminary Efficacy for ABX1100, a Muscle-targeted GYS1 siRNA, in Patients with Late-Onset Pompe Disease (LOPD)
February 6, 2026
·
5 min read
Press Releases
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
January 28, 2026
·
7 min read
Press Releases
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
December 9, 2025
·
7 min read
Press Releases
Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
October 8, 2025
·
6 min read
Press Releases
Aro Biotherapeutics Completes Enrollment in Phase 1b Trial of Targeted siRNA Therapy, ABX1100, in Late-Onset Pompe Disease (LOPD)
September 25, 2025
·
4 min read
Press Releases
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
September 10, 2025
·
7 min read
Press Releases
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity
June 2, 2025
·
6 min read
Deals
Arrowhead Nabs up to $2B Novartis Commitment for siRNA Parkinson’s Program
Novartis is licensing ARO-SNCA, a preclinical siRNA therapy for synucleinopathies, a group of neurodegenerative disorders including Parkinson’s disease.
September 2, 2025
·
1 min read
·
Annalee Armstrong
1 of 11,855
Next
